Fused pyrazole derivatives as novel erk inhibitors

A compound of Formula I:

• or the pharmaceutically acceptable salt thereof, wherein:
• X is selected from the group consisting of:
• (1) —C(R6)—, and (2) —N—;
• Y is selected from the group consisting of:
• (1) —C(R7R8)—, (2) —O—, (3) —N(R6)—, and (4) —N(R6)C(R7R8)CH2—;
• R1 is selected from the group consisting of:
• (1) aryl, and (2) heteroaryl,
• wherein said aryl and heteroaryl groups are unsubstituted or substituted by one to three R14 groups, or alternatively two R14 can optionally be taken together with the carbon atoms to which they are attached to form a five- or six-membered cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl or heteroaryl;
• R2 is selected from the group consisting of
• wherein said cycloalkyl, aryl and heteroaryl groups are unsubstituted or substituted by one to three R11 groups, or alternatively two R11 groups can optionally be taken together with the carbon atoms to which they are attached to form a five- or six-membered cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl or heteroaryl;
• R3 is selected from the group consisting of:
• (1) hydrogen, (2) alkyl, (3) haloalkyl, (4) aryl-alkyl-, and (5) heteroaryl-alkyl-,
• wherein said aryl and heteroaryl groups are unsubstituted or substituted by one to three R12 groups;
• R4 is selected from the group consisting of:
• (1) hydrogen, (2) alkyl, (3) haloalkyl, (4) carboxyl, (5) alkoxycarbonyl, (6) alkylsulfonyl-, (7) aryl-alkyl-, (8) heterocyclyl-alkyl-, (9) heteroaryl-alkyl-, (10) heterocyclyl-aryl-alkyl-, (11) aryl-heteroaryl-alkyl-, (12) aryl-aryl-alkyl-, and (13) heteroaryl-aryl-alkyl-,
• wherein said aryl, heterocyclyl and heteroaryl groups are unsubstituted or substituted by one to three R13 groups, or alternatively two R13 can optionally be taken together with the carbon atoms to which they are attached to form a five- or six-membered cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl or heteroaryl;
• each R5 is independently selected from the group consisting of:
• (1) hydrogen, (2) alkyl, (3) haloalkyl, (4) hydroxyalkyl-, (5) halo, (6) hydroxy, (7) carboxyl, (8) alkoxycarbonyl, and (9) aryl,
• wherein said aryl is unsubstituted or substituted by one to three substituents each independently selected from halo, alkyl, haloalkyl or phenyl;
• R6 is selected from the group consisting of:
• (1) hydrogen, and (2) alkyl;
• R7 and R8 independently are selected from the group consisting of (1) hydrogen, (2) alkyl, (3) haloalkyl-, (4) hydroxyalkyl-, and (5) alkoxyalkyl-, or
• alternatively R7 and R8 together with the carbon atom to which they are attached form a cycloalkyl ring;
• R9 and R10 independently are selected from the group consisting of:
• (1) hydrogen, and (2) alkyl;
• each R11 is independently selected from the group consisting of:
• (1) alkyl-, (2) haloalkyl-, (3) aryl-alkyl-, (4) halo, (5) cyano, (6) hydroxy, (7) alkoxy, (8) haloalkoxy, (9) aryloxy, (10) heteroaryloxy, (11) arylthio, (12))N(R9R10)-alkoxy-, (13) heterocycyl-alkoxy-, (14) aryl-alkyloxy-, (15) heteroaryl-alkoxy-, (16) aryl, (17) heteroaryl, (18) carboxy, (19) NR9R10, and (20) alkylsulfonyl-,
• wherein said aryl, heteroaryl, heterocyclyl is unsubstituted or substituted by one to three substituents each independently selected from alkyl, haloalkyl, halo, alkoxy, haloalkoxy, acyl, alkoxycarbonyl, heterocyclyl, heteroaryl and aryl;
• each R12 is independently selected from the group consisting of:
• (1) alkyl, (2) haloalkyl, and (3) halo;
• each R13 is independently selected from the group consisting of:
• (1) alkyl, (2) halo, (3) haloalkyl, (4) hydroxy, (5) alkoxy, (6) cyano, (7) NO2, (8) alkoxycarbonyl-, (9) acyl, (10) aryl, (11) heterocyclyl, and (12) —NR9R10;
• each R14 is independently selected from the group consisting of (1) alkyl, (2) halo, (3) haloalkyl, (4) hydroxy, (5) alkoxyl, (6) aryl;
• k is 1, 2, 3 or 4;
• and
• m is 0 or 1.